Lexaria's DehydraTECH Shows Fewer Side Effects Than Rybelsus® in Study

Lexaria Bioscience Corp. has announced promising interim results from its phase 1b study on DehydraTECH-semaglutide, showcasing a significant reduction in side effects compared to Rybelsus®, the current market leader in oral GLP-1 medications. The study, focusing on the safety and tolerability of DehydraTECH-GLP-1, revealed a 36.5% reduction in overall adverse events and a 43.5% decrease in gastrointestinal side effects with DehydraTECH-semaglutide. Lexaria's innovative drug delivery platform, DehydraTECH, is proving to be a game-changer in the treatment of obesity and type 2 diabetes, offering a more tolerable alternative to existing medications. The company's CEO, Richard Christopher, expressed optimism about the results, highlighting the potential of DehydraTECH to improve patient adherence to treatment protocols by minimizing unwanted side effects.

The study also compared the efficacy of DehydraTECH-semaglutide and DehydraTECH-tirzepatide with Rybelsus® in terms of HbA1c levels and body weight reduction. While the interim results are encouraging, Lexaria cautions that the full picture will only emerge with the completion of the 12-week study. The company's commitment to advancing drug delivery technology is evident in its robust intellectual property portfolio and ongoing research efforts. For more details, visit www.lexariabioscience.com.